MeSH term
Frequency | Condition_Probility | Humans | 491 | 0.0 |
Immunohistochemistry | 30 | 0.0 |
Prognosis | 7 | 0.0 |
Recurrence | 9 | 0.0 |
Time Factors | 32 | 0.0 |
English Abstract | 28 | 0.0 |
Amino Acid Sequence | 45 | 0.0 |
Factor Xa/metabolism | 16 | 29.0 |
Molecular Sequence Data | 49 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Arteriosclerosis/etiology | 2 | 2.0 |
Cell Line | 15 | 0.0 |
Endothelium, Vascular/*metabolism | 9 | 3.0 |
Equipment Design | 3 | 2.0 |
Perfusion | 3 | 1.0 |
Research Support, Non-U.S. Gov't | 226 | 0.0 |
Stress, Mechanical | 4 | 1.0 |
Thromboplastin/*metabolism | 36 | 22.0 |
Up-Regulation | 3 | 0.0 |
Animals | 109 | 0.0 |
Anticoagulants/*pharmacology | 21 | 23.0 |
Blood Coagulation/*drug effects | 19 | 15.0 |
Thrombosis/drug therapy | 5 | 71.0 |
Cell Division/drug effects | 5 | 0.0 |
Cricetulus | 2 | 0.0 |
Fibrinolytic Agents/*therapeutic use | 5 | 20.0 |
Hamsters | 11 | 0.0 |
Macrophages/pathology | 2 | 1.0 |
Rabbits | 26 | 0.0 |
Thrombosis/prevention & control | 3 | 27.0 |
Injections, Intravenous | 12 | 1.0 |
Injections, Subcutaneous | 12 | 3.0 |
Kinetics | 40 | 0.0 |
Lipoproteins/drug effects | 3 | 75.0 |
Male | 193 | 0.0 |
Prothrombin/antagonists & inhibitors | 3 | 42.0 |
Therapeutic Equivalency | 2 | 8.0 |
Thrombin/antagonists & inhibitors | 3 | 12.0 |
Antithrombins/metabolism | 2 | 12.0 |
Catalysis | 4 | 0.0 |
Lipoproteins/*pharmacology | 25 | 58.0 |
Prothrombin/*metabolism | 4 | 12.0 |
Research Support, U.S. Gov't, P.H.S. | 84 | 0.0 |
Adult | 150 | 0.0 |
Aged | 95 | 0.0 |
Female | 177 | 0.0 |
Lipoproteins/*blood | 83 | 13.0 |
Middle Aged | 155 | 0.0 |
Anticoagulants/administration & dosage/*pharmacology | 5 | 55.0 |
Enzyme-Linked Immunosorbent Assay | 33 | 0.0 |
Heparin, Low-Molecular-Weight/administration & dosage/*pharmacology | 4 | 100.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 5 | 4.0 |
Administration, Inhalation | 2 | 1.0 |
Blood Coagulation Tests | 12 | 6.0 |
Heparin/*administration & dosage/pharmacology | 2 | 40.0 |
Comparative Study | 74 | 0.0 |
Fibrinolysis | 8 | 5.0 |
Gene Expression Regulation/drug effects | 5 | 0.0 |
Heparin/*pharmacology | 22 | 15.0 |
Heparin, Low-Molecular-Weight/*pharmacology | 10 | 62.0 |
Lipoproteins/analysis | 8 | 34.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Thromboplastin/analysis | 6 | 23.0 |
Umbilical Veins | 7 | 1.0 |
Base Sequence | 18 | 0.0 |
Blood Coagulation Factors/*metabolism | 5 | 6.0 |
Cells, Cultured | 35 | 0.0 |
Factor VIIa/metabolism | 17 | 34.0 |
Factor X/metabolism | 10 | 18.0 |
Macromolecular Substances | 7 | 0.0 |
Protein Structure, Secondary | 6 | 0.0 |
Recombinant Proteins/metabolism/pharmacology | 3 | 2.0 |
Salivary Glands/chemistry | 2 | 40.0 |
Thromboplastin/metabolism | 19 | 24.0 |
Aged, 80 and over | 26 | 0.0 |
Anticoagulants/*blood | 9 | 69.0 |
Cross-Sectional Studies | 3 | 0.0 |
Japan | 2 | 0.0 |
Plasminogen Activator Inhibitor 1/*blood | 2 | 6.0 |
Reference Values | 26 | 0.0 |
Serine Proteinase Inhibitors/*blood | 10 | 62.0 |
Biological Markers/blood | 19 | 1.0 |
Blood Coagulation/*physiology | 17 | 14.0 |
Cell Division | 4 | 0.0 |
Endothelium, Vascular/cytology/*physiology | 4 | 6.0 |
Factor VIIa/physiology | 2 | 50.0 |
Factor Xa/antagonists & inhibitors | 33 | 70.0 |
Mice | 14 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Recombinant Proteins/therapeutic use | 9 | 2.0 |
Gestational Age | 2 | 0.0 |
Heparin/pharmacology | 29 | 11.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Binding Sites | 17 | 0.0 |
Factor VIIa/antagonists & inhibitors | 6 | 66.0 |
Models, Molecular | 8 | 0.0 |
Prothrombin/metabolism | 9 | 12.0 |
Recombinant Proteins/chemistry/pharmacology | 3 | 13.0 |
Models, Biological | 7 | 0.0 |
Blood Coagulation Factors/metabolism | 13 | 24.0 |
Case-Control Studies | 37 | 0.0 |
Thrombophilia/blood/*etiology | 4 | 44.0 |
Endothelium, Vascular/physiopathology | 3 | 8.0 |
*Hemostasis | 10 | 7.0 |
Lipoproteins/blood | 13 | 3.0 |
Plasminogen Activator Inhibitor 1/blood | 12 | 10.0 |
Platelet Activation | 2 | 1.0 |
Protein C/physiology | 4 | 15.0 |
Species Specificity | 8 | 0.0 |
Thrombomodulin/blood | 4 | 11.0 |
*Blood Coagulation | 21 | 9.0 |
*Models, Biological | 3 | 1.0 |
Disease Progression | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Blood Coagulation Factors/drug effects/metabolism | 2 | 33.0 |
Disease Models, Animal | 6 | 0.0 |
Acute Disease | 8 | 0.0 |
Partial Thromboplastin Time | 12 | 6.0 |
Prospective Studies | 14 | 0.0 |
Vitamin K/antagonists & inhibitors | 2 | 33.0 |
Clinical Trials, Phase III | 2 | 4.0 |
Factor Xa/*antagonists & inhibitors | 29 | 80.0 |
Randomized Controlled Trials | 2 | 0.0 |
Treatment Outcome | 12 | 0.0 |
Factor Xa/*metabolism | 8 | 36.0 |
Fibrin/analysis | 2 | 6.0 |
Fibrin Fibrinogen Degradation Products/analysis | 6 | 4.0 |
Hematologic Neoplasms/blood | 2 | 28.0 |
Hemostasis | 11 | 10.0 |
Lipoproteins/*blood/metabolism | 4 | 30.0 |
Neoplasms/*blood | 2 | 4.0 |
Protein Binding | 23 | 0.0 |
Adolescent | 27 | 0.0 |
*Cardiopulmonary Bypass | 3 | 3.0 |
Cohort Studies | 5 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Anticoagulants/pharmacology | 8 | 11.0 |
Peptide Fragments/chemistry/metabolism | 3 | 2.0 |
Blotting, Northern | 9 | 0.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Rats | 14 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Umbilical Veins/cytology | 6 | 2.0 |
Risk Factors | 21 | 0.0 |
Cell Membrane/metabolism | 6 | 0.0 |
Drug Evaluation, Preclinical | 3 | 1.0 |
Fibrinolytic Agents/*pharmacology | 9 | 29.0 |
*Hemorheology | 2 | 7.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Secretory Rate/drug effects | 2 | 2.0 |
Endothelium, Vascular/cytology/*metabolism | 4 | 2.0 |
Lipoproteins/*biosynthesis/genetics | 3 | 75.0 |
Anticoagulants/*therapeutic use | 8 | 17.0 |
Antithrombin III/therapeutic use | 2 | 50.0 |
Clinical Trials | 4 | 0.0 |
In Vitro | 16 | 0.0 |
Protein C/therapeutic use | 2 | 40.0 |
Anticoagulants/therapeutic use | 6 | 8.0 |
Drug Interactions | 6 | 0.0 |
Anticoagulants/*metabolism | 10 | 32.0 |
Heparin/*metabolism | 4 | 4.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Protein Conformation | 7 | 0.0 |
Fibrinolytic Agents/*blood | 4 | 80.0 |
Blood Coagulation | 12 | 7.0 |
Pregnancy | 11 | 0.0 |
Signal Transduction | 2 | 0.0 |
Thromboplastin/*physiology | 8 | 22.0 |
Cell Adhesion | 2 | 0.0 |
Enzyme Activation | 4 | 0.0 |
Lipoproteins/genetics/*physiology | 3 | 75.0 |
Swine | 7 | 0.0 |
Thrombin/*pharmacology | 4 | 3.0 |
Thrombosis/*prevention & control | 4 | 22.0 |
Transfection | 4 | 0.0 |
Biological Markers | 10 | 0.0 |
Cardiovascular Diseases/blood | 3 | 15.0 |
Kidney Failure, Chronic/*blood | 3 | 4.0 |
Thrombomodulin/analysis | 4 | 14.0 |
Dose-Response Relationship, Drug | 20 | 0.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
Lipoproteins/*physiology | 7 | 58.0 |
Thromboplastin/pharmacology | 2 | 15.0 |
Hemostasis/drug effects | 3 | 9.0 |
Lipids/blood | 11 | 1.0 |
Serine Proteinase Inhibitors/blood | 4 | 50.0 |
Activated Protein C Resistance/*chemically induced/genetics | 2 | 100.0 |
Double-Blind Method | 16 | 0.0 |
Drug Combinations | 2 | 0.0 |
Estrogen Replacement Therapy/*adverse effects | 3 | 21.0 |
Factor V/genetics | 2 | 2.0 |
Follow-Up Studies | 11 | 0.0 |
Heterozygote | 3 | 0.0 |
Mutation | 5 | 0.0 |
CHO Cells | 7 | 0.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Plasminogen/metabolism | 2 | 5.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Structure-Activity Relationship | 12 | 0.0 |
Blood Cell Count | 2 | 0.0 |
Blood Coagulation/drug effects | 13 | 11.0 |
Blood Coagulation/physiology | 15 | 25.0 |
Endothelium, Vascular/metabolism | 13 | 5.0 |
Neoplasm Metastasis | 2 | 0.0 |
Neoplasms/blood | 2 | 5.0 |
Sequence Alignment | 5 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Thromboplastin/physiology | 3 | 18.0 |
Molecular Weight | 9 | 0.0 |
Solubility | 4 | 0.0 |
Blotting, Western | 5 | 0.0 |
Cells, Cultured/drug effects/metabolism | 2 | 4.0 |
Coronary Arteriosclerosis/*metabolism | 2 | 33.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 2 | 2.0 |
Lipoproteins/*metabolism | 31 | 20.0 |
Antiphospholipid Syndrome/*blood | 2 | 28.0 |
Thrombosis/*blood | 2 | 7.0 |
Disseminated Intravascular Coagulation/prevention & control | 2 | 66.0 |
Lipoproteins/*administration & dosage/pharmacology | 2 | 100.0 |
Statistics, Nonparametric | 8 | 0.0 |
Survival Analysis | 4 | 0.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Alleles | 2 | 0.0 |
Angioplasty, Transluminal, Percutaneous Coronary/adverse effects | 2 | 33.0 |
Lipoproteins/*genetics | 11 | 32.0 |
Polymorphism, Genetic | 2 | 0.0 |
Heparin/administration & dosage/*pharmacology | 6 | 46.0 |
Heparin, Low-Molecular-Weight/administration & dosage/pharmacology | 2 | 50.0 |
Syndrome | 3 | 0.0 |
Anticoagulants/pharmacology/*therapeutic use | 3 | 75.0 |
Fibrinolytic Agents/pharmacology/*therapeutic use | 2 | 50.0 |
Inflammation | 6 | 1.0 |
Thromboplastin/*antagonists & inhibitors/*physiology | 3 | 75.0 |
Endothelium, Vascular/*secretion | 2 | 25.0 |
Enoxaparin/*pharmacology | 4 | 57.0 |
Lipoproteins/blood/*secretion | 3 | 100.0 |
Endothelium, Vascular/*pathology | 3 | 4.0 |
Thrombomodulin/*blood | 6 | 23.0 |
Infusions, Intravenous | 8 | 1.0 |
Lipoproteins/blood/*drug effects | 2 | 20.0 |
Cross-Over Studies | 9 | 1.0 |
Family Health | 2 | 0.0 |
Anticoagulants/blood | 12 | 70.0 |
Age Factors | 10 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 5 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 9 | 1.0 |
Thrombin/metabolism | 6 | 4.0 |
Analysis of Variance | 10 | 0.0 |
DNA Primers | 3 | 0.0 |
Gene Frequency | 4 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Venous Thrombosis/*blood | 2 | 16.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Thrombomodulin/*metabolism | 2 | 8.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 6 | 0.0 |
Infant | 2 | 0.0 |
Point Mutation | 4 | 0.0 |
Prevalence | 2 | 0.0 |
Protein Binding/drug effects | 4 | 1.0 |
Recombinant Proteins/pharmacology | 10 | 0.0 |
Lipoproteins/*blood/drug effects | 3 | 30.0 |
Leukocytes/immunology | 3 | 2.0 |
Lipopolysaccharides/administration & dosage | 2 | 7.0 |
Lipoproteins/administration & dosage/*pharmacology | 2 | 100.0 |
Antithrombin III/analysis | 4 | 2.0 |
Chromatography, Gel | 7 | 0.0 |
Peptide Hydrolases/analysis | 4 | 3.0 |
Polysaccharide-Lyases/pharmacology | 2 | 12.0 |
Prothrombin Time | 12 | 11.0 |
RNA, Messenger/analysis | 7 | 0.0 |
Thromboplastin/drug effects/metabolism | 2 | 33.0 |
Fibrin/metabolism | 7 | 11.0 |
Antifibrinolytic Agents/metabolism | 2 | 9.0 |
Factor VII/metabolism | 12 | 30.0 |
Fibrinogen/metabolism | 4 | 1.0 |
Linear Models | 3 | 0.0 |
Lipoproteins/metabolism | 9 | 8.0 |
Matched-Pair Analysis | 3 | 3.0 |
Protein S/metabolism | 2 | 5.0 |
Thrombosis/blood/etiology | 2 | 16.0 |
Models, Chemical | 3 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Thromboplastin/*analysis | 17 | 37.0 |
Lipoproteins/*analysis/blood | 2 | 40.0 |
Body Mass Index | 7 | 0.0 |
Cholesterol/blood | 6 | 0.0 |
Factor VII/*analysis | 4 | 22.0 |
Monocytes/physiology | 3 | 2.0 |
Brain/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Recombinant Proteins/metabolism | 16 | 0.0 |
Tumor Cells, Cultured | 12 | 0.0 |
Carbohydrate Sequence | 2 | 0.0 |
Molecular Structure | 2 | 0.0 |
Lipoproteins/chemistry/metabolism/*pharmacology | 2 | 66.0 |
Adenoviridae/genetics | 3 | 0.0 |
Tunica Intima/*pathology | 2 | 10.0 |
*Coronary Angiography | 2 | 8.0 |
Hemostatics/blood | 2 | 66.0 |
Regression Analysis | 5 | 0.0 |
Anticoagulants/blood/therapeutic use | 2 | 66.0 |
Fibrinopeptide A/metabolism | 2 | 8.0 |
Thrombin/*biosynthesis | 4 | 12.0 |
Lipoproteins/chemistry/*physiology | 2 | 100.0 |
Anticoagulants/metabolism | 5 | 29.0 |
Biopsy | 2 | 0.0 |
Endothelium, Vascular/*drug effects/metabolism | 3 | 5.0 |
Hemostasis/*drug effects | 4 | 6.0 |
Lipoproteins/drug effects/metabolism | 2 | 66.0 |
Incidence | 4 | 0.0 |
Platelet Count | 4 | 0.0 |
Disseminated Intravascular Coagulation/*blood/etiology | 3 | 27.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 5 | 5.0 |
Fibrinolytic Agents/blood | 7 | 58.0 |
Lipoproteins/biosynthesis/*genetics | 2 | 100.0 |
Models, Animal | 3 | 1.0 |
Recombinant Proteins | 8 | 1.0 |
Factor Xa/antagonists & inhibitors/metabolism | 5 | 62.0 |
Gene Expression | 7 | 0.0 |
Kidney/metabolism | 2 | 0.0 |
Liver/metabolism | 4 | 0.0 |
Phenotype | 2 | 0.0 |
Angioplasty, Transluminal, Percutaneous Coronary | 3 | 6.0 |
Coronary Angiography | 5 | 2.0 |
Antithrombins/*metabolism | 3 | 30.0 |
Factor VIIa/*metabolism | 6 | 15.0 |
Fibrinolytic Agents/*pharmacology/therapeutic use | 2 | 66.0 |
Antigens/metabolism | 3 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Factor VII/analysis | 2 | 6.0 |
Sensitivity and Specificity | 6 | 0.0 |
Drug Synergism | 5 | 0.0 |
Thromboplastin/*antagonists & inhibitors | 8 | 38.0 |
Anticoagulants/*analysis | 3 | 100.0 |
Lipoproteins/*analysis | 10 | 52.0 |
Factor VIIa/analysis | 2 | 33.0 |
Tissue Plasminogen Activator/blood | 7 | 6.0 |
Culture Media | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Oxidation-Reduction | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Anticoagulants/blood/metabolism | 3 | 75.0 |
Thrombophilia/blood | 4 | 50.0 |
Myocardial Infarction/*blood | 4 | 6.0 |
Disseminated Intravascular Coagulation/*blood | 5 | 23.0 |
Factor Xa/antagonists & inhibitors/*metabolism | 3 | 50.0 |
Fibrinolytic Agents/metabolism | 5 | 41.0 |
Cell Movement/drug effects | 2 | 0.0 |
Endothelium, Vascular/*cytology | 2 | 1.0 |
Genotype | 5 | 0.0 |
Lipoproteins/blood/*genetics | 2 | 28.0 |
Peptide Fragments/blood | 4 | 3.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Prothrombin | 3 | 6.0 |
Restriction Mapping | 3 | 0.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Hemostatics/pharmacology | 2 | 8.0 |
Serine Proteinase Inhibitors/metabolism | 2 | 25.0 |
*Postmenopause | 2 | 3.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Heparin/blood | 2 | 14.0 |
Intraoperative Period | 2 | 3.0 |
Peptide Fragments/analysis | 6 | 2.0 |
Prothrombin/analysis | 5 | 6.0 |
Antibodies/pharmacology | 2 | 0.0 |
Down-Regulation | 4 | 0.0 |
Factor VIIa/antagonists & inhibitors/metabolism | 4 | 80.0 |
Substrate Specificity | 2 | 0.0 |
Antithrombin III/metabolism | 10 | 8.0 |
Homocysteine/*blood | 2 | 0.0 |
Peptide Hydrolases/metabolism | 5 | 3.0 |
Coronary Disease/*blood | 2 | 3.0 |
Flow Cytometry | 5 | 0.0 |
Lipoproteins/*blood/immunology | 3 | 60.0 |
Severity of Illness Index | 5 | 0.0 |
Lipoproteins/analysis/*genetics | 2 | 100.0 |
*Orthopedics | 2 | 100.0 |
Arteriosclerosis/*metabolism/pathology | 2 | 5.0 |
Endothelium, Vascular/chemistry | 3 | 5.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
*Gene Expression | 2 | 0.0 |
Macrophages/chemistry | 2 | 8.0 |
Microscopy, Confocal | 2 | 0.0 |
Muscle, Smooth, Vascular/chemistry | 2 | 18.0 |
*Antiplasmin | 2 | 4.0 |
Renal Dialysis/*adverse effects | 3 | 2.0 |
Blood Coagulation/drug effects/physiology | 2 | 16.0 |
Blood Platelets/physiology | 3 | 5.0 |
Lipoproteins/physiology | 6 | 66.0 |
Factor IX/metabolism | 3 | 21.0 |
Hemostasis/*physiology | 2 | 3.0 |
Antigens/blood | 5 | 9.0 |
Endothelium, Vascular/metabolism/pathology | 2 | 3.0 |
Plasmin/metabolism | 2 | 2.0 |
United States | 2 | 0.0 |
Binding, Competitive | 8 | 0.0 |
Cell Membrane/*metabolism | 5 | 1.0 |
Chromatography, Affinity | 6 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Amides/metabolism | 2 | 13.0 |
Antithrombins/pharmacology | 2 | 16.0 |
Cattle | 11 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Drug Administration Schedule | 6 | 0.0 |
Fibrinolysis/drug effects | 2 | 5.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Predictive Value of Tests | 3 | 0.0 |
von Willebrand Factor/*metabolism | 2 | 0.0 |
Heparin | 3 | 4.0 |
Lipoproteins/*biosynthesis | 4 | 30.0 |
Neovascularization, Pathologic | 2 | 0.0 |
Thromboplastin/*biosynthesis | 7 | 9.0 |
Anticoagulants/*metabolism/pharmacology | 3 | 42.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Lipoproteins/*metabolism/pharmacology | 4 | 100.0 |
Administration, Cutaneous | 4 | 4.0 |
Peptide Fragments/pharmacology | 3 | 1.0 |
Thromboplastin/*antagonists & inhibitors/chemistry | 2 | 100.0 |
Blood Pressure | 4 | 0.0 |
Thrombomodulin/metabolism | 2 | 6.0 |
Thrombosis/blood/immunology | 2 | 66.0 |
Body Weight | 2 | 0.0 |
Endothelium, Vascular/*physiology | 6 | 4.0 |
Dietary Fats, Unsaturated/*administration & dosage | 2 | 10.0 |
Triglycerides/blood | 4 | 0.0 |
Lipoproteins/biosynthesis | 4 | 28.0 |
*Renal Dialysis | 5 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Monocytes/cytology/*metabolism | 2 | 7.0 |
Thrombin/biosynthesis | 6 | 15.0 |
Factor VIII/metabolism | 5 | 5.0 |
Protein C/metabolism | 7 | 7.0 |
Thrombin/*metabolism | 4 | 5.0 |
Lipoproteins/*genetics/metabolism | 2 | 28.0 |
Tissue Distribution | 2 | 0.0 |
Apolipoproteins B/blood | 2 | 0.0 |
Fatty Acids, Monounsaturated/*administration & dosage | 2 | 28.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Heparin, Low-Molecular-Weight/pharmacology | 4 | 36.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Biological Transport | 3 | 0.0 |
Dogs | 2 | 0.0 |
Phospholipids/*metabolism | 3 | 2.0 |
Fibrinogen/analysis | 2 | 1.0 |
Fibrinopeptide A/analysis | 2 | 4.0 |
von Willebrand Factor/analysis | 4 | 1.0 |
Homozygote | 2 | 0.0 |
Venous Thrombosis/*genetics | 2 | 18.0 |
Cadaver | 2 | 0.0 |
Tissue Plasminogen Activator/metabolism | 2 | 5.0 |
von Willebrand Factor/metabolism | 4 | 1.0 |
*Angioplasty, Transluminal, Percutaneous Coronary | 2 | 4.0 |
Chronic Disease | 3 | 0.0 |
Factor Xa/physiology | 2 | 100.0 |
Fibrinolytic Agents/therapeutic use | 2 | 11.0 |
Fibrinolysis/*physiology | 6 | 7.0 |
Drug Therapy, Combination | 3 | 0.0 |
Endothelium, Vascular/drug effects/metabolism | 2 | 3.0 |
Heparin, Low-Molecular-Weight/*therapeutic use | 3 | 15.0 |
Nadroparin/therapeutic use | 2 | 100.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Thrombin/pharmacology | 5 | 2.0 |
Receptors, LDL/metabolism | 2 | 2.0 |
Platelet Aggregation | 2 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Whole Blood Coagulation Time | 4 | 23.0 |
Angina, Unstable/blood | 2 | 25.0 |
Blood Coagulation Factors | 3 | 33.0 |
Heparin/*administration & dosage | 5 | 16.0 |
Hyperlipidemia/blood | 2 | 5.0 |
Endotoxins/*pharmacology | 3 | 3.0 |
Necrosis | 2 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Heparin/therapeutic use | 6 | 14.0 |
Antigens/biosynthesis | 2 | 20.0 |
Kidney Glomerulus/metabolism/pathology | 2 | 16.0 |
Thromboplastin/biosynthesis | 3 | 17.0 |
Thrombosis/etiology/*prevention & control | 3 | 50.0 |
France/epidemiology | 2 | 1.0 |
Thrombosis/*blood/etiology | 2 | 22.0 |
Pedigree | 3 | 0.0 |
Lipoproteins/genetics/*metabolism | 3 | 25.0 |
Cloning, Molecular | 12 | 0.0 |
Sequence Analysis | 4 | 1.0 |
Lipoproteins/*immunology | 3 | 17.0 |
Fibrinolysis/physiology | 2 | 4.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Thrombin/physiology | 4 | 11.0 |
Retrospective Studies | 2 | 0.0 |
Epoprostenol/metabolism | 2 | 11.0 |
Thrombomodulin/physiology | 3 | 27.0 |
*Signal Transduction | 2 | 0.0 |
Factor VIIa/*antagonists & inhibitors | 6 | 85.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Lipoproteins/*chemistry/metabolism | 4 | 66.0 |
Factor VII/*metabolism | 3 | 13.0 |
Anticoagulants/*administration & dosage | 4 | 9.0 |
Antithrombins/analysis | 4 | 25.0 |
Antigens/*blood | 3 | 12.0 |
Monocytes/*metabolism | 3 | 0.0 |
Thrombosis/*metabolism | 2 | 28.0 |
Kallikreins/metabolism | 2 | 13.0 |
Antithrombin III/*metabolism | 4 | 6.0 |
Phospholipids/metabolism | 4 | 2.0 |
Phospholipids/chemistry/*metabolism | 2 | 33.0 |
Membrane Lipids/metabolism | 2 | 4.0 |
Phosphatidylcholines/metabolism | 2 | 2.0 |
Circadian Rhythm | 2 | 0.0 |
Drug Resistance | 2 | 0.0 |
Protein C/*pharmacology | 2 | 3.0 |
Protein S/analysis | 2 | 5.0 |
Lipoproteins/genetics/*pharmacology | 2 | 50.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
*Caveolins | 2 | 5.0 |
Cell Compartmentation | 2 | 0.0 |
Cell Fractionation | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Chlorates/pharmacology | 3 | 18.0 |
*Endocytosis | 2 | 1.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Glycosylphosphatidylinositols/metabolism | 4 | 7.0 |
Lipoproteins/*analysis/isolation & purification | 2 | 100.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 3 | 3.0 |
Phospholipase C/metabolism | 3 | 1.0 |
Urinary Plasminogen Activator/analysis | 2 | 12.0 |
Infant, Newborn | 5 | 0.0 |
Recombinant Proteins/*pharmacology | 2 | 2.0 |
Glycosaminoglycans/*metabolism | 2 | 8.0 |
Fibrinolytic Agents/*metabolism | 4 | 50.0 |
Endothelium, Vascular/*metabolism/ultrastructure | 2 | 13.0 |
Microscopy, Electron | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Heparin/metabolism | 2 | 1.0 |
Thromboplastin/genetics/*metabolism | 3 | 10.0 |
Fibrin/*metabolism | 2 | 5.0 |
Anticholesteremic Agents/*administration & dosage | 2 | 20.0 |
Glycosaminoglycans/*pharmacology | 2 | 25.0 |
Crystallography, X-Ray | 2 | 0.0 |
Factor Xa/chemistry/*metabolism | 2 | 33.0 |
Protamines/*pharmacology | 3 | 25.0 |
Smoking | 2 | 0.0 |
Serine Proteinase Inhibitors/*pharmacology | 7 | 16.0 |
Fibrinolytic Agents/*metabolism/pharmacology | 2 | 66.0 |
Lipoproteins/genetics/*metabolism/pharmacology | 2 | 100.0 |
Lung/metabolism | 2 | 1.0 |
Monocytes/metabolism | 2 | 0.0 |
Lipoproteins, LDL/*blood | 2 | 1.0 |
Recombinant Proteins/blood | 4 | 26.0 |
Antithrombin III/*pharmacology | 2 | 33.0 |
Protamines | 2 | 28.0 |
Blood Coagulation Factors/*physiology | 2 | 8.0 |
Diabetes Mellitus/*blood | 2 | 2.0 |
Lipoproteins, LDL/metabolism | 4 | 1.0 |
Lipoproteins/chemistry/*metabolism/pharmacology | 2 | 100.0 |
Surface Properties | 2 | 1.0 |
Factor Xa/*antagonists & inhibitors/metabolism | 3 | 100.0 |
Hyperlipidemia/*blood | 2 | 5.0 |
Recombinant Proteins/biosynthesis/pharmacology | 2 | 6.0 |
Transcription, Genetic | 2 | 0.0 |
Blood Coagulation Factors/*analysis | 2 | 2.0 |
Heparin/administration & dosage | 2 | 8.0 |
Odds Ratio | 4 | 0.0 |
Endothelium, Vascular/*physiopathology | 2 | 2.0 |
Hirudins/pharmacology | 2 | 10.0 |
Lipopolysaccharides/*pharmacology | 3 | 0.0 |
Thrombin Time | 2 | 9.0 |
Factor X/pharmacology | 2 | 40.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Factor Xa/analysis | 2 | 50.0 |
LDL-Receptor Related Protein 1 | 2 | 1.0 |
Cell Membrane/chemistry/metabolism | 2 | 4.0 |
Chromogenic Compounds/metabolism | 2 | 25.0 |
Heparin, Low-Molecular-Weight/therapeutic use | 2 | 22.0 |
Lipoproteins/drug effects/*metabolism | 2 | 66.0 |
Thrombophlebitis/prevention & control | 2 | 40.0 |
Calcium/pharmacology | 3 | 1.0 |
Lipoproteins/chemistry/genetics/*pharmacology | 2 | 100.0 |
Phospholipids/pharmacology | 3 | 9.0 |
Biological Availability | 2 | 0.0 |
Protamines/pharmacology | 2 | 13.0 |
Thrombosis/blood/*drug therapy | 2 | 66.0 |
Anastomosis, Surgical | 2 | 10.0 |
Lipoproteins/pharmacology | 4 | 18.0 |
Serine Proteinase Inhibitors/*metabolism | 4 | 17.0 |
Lipoproteins/chemistry/*pharmacology | 2 | 100.0 |
Thromboplastin/antagonists & inhibitors | 3 | 42.0 |
Computer Simulation | 2 | 0.0 |
Tissue Plasminogen Activator/pharmacology | 2 | 18.0 |
Blood Coagulation Factors/analysis | 4 | 6.0 |
Tissue Plasminogen Activator/analysis | 4 | 10.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Placebos | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Macrophages/metabolism | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Lipoproteins, LDL/blood | 2 | 0.0 |
Lipoproteins, VLDL/blood | 2 | 0.0 |
Plasma | 2 | 3.0 |
Thrombosis/etiology | 3 | 4.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Factor VII/antagonists & inhibitors | 2 | 66.0 |
Factor VIIa/*antagonists & inhibitors/metabolism | 2 | 40.0 |
Ovarian Neoplasms | 2 | 5.0 |
Thromboplastin/*antagonists & inhibitors/metabolism | 3 | 30.0 |
Chromogenic Compounds | 2 | 9.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Blood Coagulation Factors/physiology | 2 | 15.0 |
Endothelium, Vascular | 2 | 4.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Spectrum Analysis, Mass | 4 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Hemorrhage/etiology | 2 | 9.0 |
Heparin, Low-Molecular-Weight/*pharmacology/therapeutic use | 2 | 100.0 |
Osmolar Concentration | 2 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Endothelium, Vascular/cytology/drug effects | 2 | 3.0 |
Mice, Inbred C57BL | 2 | 0.0 |
*Chromosomes, Human, Pair 2 | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Protease Inhibitors/*metabolism | 2 | 11.0 |
Rabbits/*blood | 2 | 50.0 |
Lipoproteins/*secretion | 2 | 25.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 3 | 7.0 |
Factor VII/*antagonists & inhibitors/genetics | 4 | 100.0 |
Thromboplastin/*antagonists & inhibitors/genetics | 4 | 44.0 |
Cathepsins/antagonists & inhibitors/*blood | 2 | 100.0 |
Neutrophils/*enzymology | 2 | 1.0 |
Pancreatic Elastase/antagonists & inhibitors/*blood | 2 | 100.0 |
Protease Inhibitors/*blood | 2 | 14.0 |
DNA/*genetics | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Aorta | 2 | 1.0 |
Fibrinolytic Agents/pharmacology | 2 | 9.0 |
Statistics | 2 | 0.0 |
Kidney Failure, Chronic/therapy | 2 | 5.0 |
Platelet Aggregation/*drug effects | 2 | 1.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
Venous Thrombosis/blood/*etiology | 2 | 66.0 |
Lipoproteins/*analysis/physiology | 2 | 100.0 |
Lipoproteins/blood/drug effects | 2 | 14.0 |
Thromboplastin/analysis/drug effects | 2 | 100.0 |
Blood Coagulation Factor Inhibitors | 2 | 66.0 |
